CHF Solutions Expands Commercial Presence in Europe with Distribution Arrangement for Germany, Austria and Switzerland
February 12 2020 - 9:15AM
CHF Solutions (Nasdaq: CHFS) today announced the initiation of
distribution agreements covering Germany, Austria and Switzerland
with Neucomed Group and its affiliates, further expanding its
commercial presence in the European Union. The company now has
distribution partnerships covering 13 countries worldwide.
Approximately 2.0 million individuals suffer from heart failure
in these three countries, including 1.4 million individuals in
Germany.1,2,3 The company further estimates that, in Germany,
there are approximately 225,000 hospitalizations each year for
heart failure due to fluid overload, of which approximately 150,000
patients (68%) experience fluid overload with less than optimal
diuretic response.4
“We continue to execute on our goal to expand worldwide access
to aquapheresis therapy,” said John Erb, chairman and CEO of CHF
Solutions. “With the recently-announced receipt of the CE Mark for
our next generation Aquadex SmartFlow™ console, we are able to
provide this simple, flexible and smart solution to patients in the
EU suffering from fluid overload due to heart failure,
cardiovascular surgery and other critical care conditions and are
looking forward to working with Neucomed.”
“We are pleased to be partnering with CHF Solutions, and look
forward to bringing the new Aquadex SmartFlow system to heart
failure patients in central Europe,” said Erwin Mueller, Chief
Executive Officer of Neucomed Group.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company
dedicated to changing the lives of patients suffering from fluid
overload through science, collaboration, and innovative technology.
The company is focused on developing, manufacturing, and
commercializing the Aquadex FlexFlow® and Aquadex SmartFlow systems
for ultrafiltration therapy. CHF Solutions is a Delaware
corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
About Aquadex FlexFlow and Aquadex SmartFlow
Systems
The Aquadex FlexFlow and Aquadex SmartFlow systems are
clinically proven therapies that provide a safe, effective, and
predictable method of removing excess fluid from patients suffering
from fluid overload. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy, and for
extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and
require hospitalization. The company has submitted an application
to the FDA requesting for 510(k) clearance of the Aquadex SmartFlow
system, including pediatric patients who weigh 20kg or more. All
treatments must be administered by a healthcare provider, under
physician prescription, both of whom having received training in
extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the company’s growth internationally.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal DraytonChief Financial Officer CHF Solutions,
Inc.952-345-4205ir@chf-solutions.com
-or-
Bret Shapiro Managing Partner CORE IR 516-222-2560
brets@coreir.com www.coreir.com
MEDIA: Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
1. Cardiac Failure Review 2017; 3(1):7-11.2. Swiss Med Wkly.
2011;141:w13171.3. The European Journal of Heart Failure 6 (2004)
947– 952.4. Testani, et.al. “Early Rapidly and Highly Accurate
Prediction of Poor Loop Diurectic Natriuretic Response
in Patients with Heart Failure.” Circ Heart Fail. 2016;
9:e002370.
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024